Geneva University Hospitals (HUG), the University of Geneva (UNIGE), the Infectious Disease Research Centre at Laval University in Quebec (Canada) and MaxiVAX – a Geneva-based company specialising in biotechnology – are working together to develop a SARS-CoV-2 vaccine. This joint research programme aims to create a vaccine combining an immunostimulator and a specific coronavirus target, namely the spike surface protein.
This is administered by intradermal injection with the immunostimulator, whose role is to produce an adjuvant capable of stimulating the immune system. It is implanted under the skin via cell encapsulation, a technology that is already undergoing Phase II clinical tests led by HUG in collaboration with MaxiVAX in the area of cancer immunotherapy.
The first pre-clinical tests for perfecting the vaccine will be carried out on mice in the coming weeks. If preliminary tests prove encouraging, a clinical trial could be set up in the near future.
MaxiVAX is a Swiss clinical-stage biotechnology company which, having completed a first-in-man Phase I clinical study, is now planning to perform several Phase II multicenter studies in different types of cancer.
First generation cancer immunotherapies are paving the way for MaxiVAX’s personalized immunotherapy.
A novel and proprietary way to reprogram and boost the patient’s own immune system for fighting cancer.
Campus Biotech Innovation Park
Avenue de Sécheron 15
+41 22 552 26 13